ASX-173
Product Specifications
CAS Number
2748800-08-8
Target
CDK|||ATG|||Autophagy|||Apoptosis|||Akt|||PARP|||Caspase
Related Pathways
Apoptosis|||Cell Cycle/Checkpoint|||Autophagy|||Cytoskeletal Signaling|||Proteases/Proteasome|||PI3K/Akt/mTOR signaling|||DNA Damage/DNA Repair|||Chromatin/Epigenetic
Bioactivity
ASX-173 is an orally active asparagine synthetase (ASNS) inhibitor with an IC50 of 0.113 ?M and a Ki of 0.4 nM. It enhances the anticancer activity of L-Asparaginase (ASNase) . When combined with ASNase, ASX-173 disrupts nucleotide synthesis and induces cell cycle arrest, apoptosis (apoptosis), and autophagy (autophagy) in leukemia cells. This combination also slows the growth of OCI-AML2 xenograft tumors. ASX-173 is applicable in research on acute lymphoblastic leukemia, acute myeloid leukemia, colorectal cancer, and other cancers.
Smiles
C(NC(C1=CC=CC=C1)C2=CC=CC=C2)(=O)[C@@H]3N(C([C@H](CC)N)=O)C[C@H]([C@@H]3O)C4=CC=C(F)C=C4
Molecular Formula
C28H30FN3O3
Molecular Weight
475.56
Shipping Conditions
Cool pack
Storage Temperature
-20°C
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
134106-PE 100 µL
SURF5 (MED22, Mediator of RNA Polymerase II Transcription Subunit 22, Mediator Complex Subunit 22, Surfeit Locus Protein 5, Surf-5, MGC48682) (PE)
Ask
View Details